Education
About Us
Working with TipRanks
Follow Us
Cogent Biosciences (COGT)
NASDAQ:COGT
COGT Stock Chart & Stats
$35.57
-$0.07(-0.91%)
At close: 4:00 PM EST
$35.57
-$0.07(-0.91%)
Day’s Range― - ―
52-Week Range$3.72 - $43.73
Previous CloseN/A
Volume181.15K
Average Volume (3M)2.30M
Market Cap
$5.51B
Enterprise Value$1.75B
Total Cash (Recent Filing)$390.89M
Total Debt (Recent Filing)$60.56M
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Mar 17, 2026EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding152,053,960
10 Day Avg. Volume1,681,916
30 Day Avg. Volume2,298,967
Financial Highlights & Ratios
PEG Ratio-1.92
Price to Book (P/B)3.16
Price to Sales (P/S)0.00
P/FCF Ratio-3.89
Enterprise Value/Market Cap0.32
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.51K
Enterprise Value/Ebitda-5.90
Forecast
1Y Price Target
$48.70Price Target Upside36.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy In Systemic MastocytosisSUMMIT and APEX findings showed notable symptom reductions and substantial declines in serum tryptase, reinforcing efficacy in non-advanced systemic mastocytosis and potential label expansion.
Clinical Trial Results — 2L GISTPhase 3 PEAK data indicate the bezuclastinib plus sunitinib combination substantially improved progression-free survival and response rates versus sunitinib alone, supporting potential adoption as a new second-line standard in GIST.
Regulatory And Commercial OutlookManagement plans for multiple NDA submissions combined with analyst upgrades and a higher price target reflect an expectation of meaningful commercial upside if approvals and launches proceed.
Bears Say
Comparative Response Versus CompetitorReported overall response rate for bezuclastinib was lower than a leading competitor's, which may reduce physician preference in situations where higher response benchmarks exist.
Competitive Risk In 2L GISTInvestor concern about a rival program entering Phase 3 for second-line GIST presents downside risk to future market share and pricing for the bezuclastinib regimen.
Safety Concerns And Hepatic EventsReports of transient but serious liver enzyme elevations and some treatment discontinuations increase the likelihood of stricter monitoring requirements that could hinder broader clinical uptake.
Cogent Biosciences News
COGT FAQ
What was Cogent Biosciences’s price range in the past 12 months?
Cogent Biosciences lowest stock price was $3.72 and its highest was $43.73 in the past 12 months.
What is Cogent Biosciences’s market cap?
Cogent Biosciences’s market cap is $5.51B.
When is Cogent Biosciences’s upcoming earnings report date?
Cogent Biosciences’s upcoming earnings report date is Mar 17, 2026 which is in 67 days.
How were Cogent Biosciences’s earnings last quarter?
Cogent Biosciences released its earnings results on Nov 03, 2025. The company reported -$0.5 earnings per share for the quarter, beating the consensus estimate of -$0.516 by $0.016.
Is Cogent Biosciences overvalued?
According to Wall Street analysts Cogent Biosciences’s price is currently Undervalued.
Does Cogent Biosciences pay dividends?
Cogent Biosciences does not currently pay dividends.
What is Cogent Biosciences’s EPS estimate?
Cogent Biosciences’s EPS estimate is -0.51.
How many shares outstanding does Cogent Biosciences have?
Cogent Biosciences has 152,053,960 shares outstanding.
What happened to Cogent Biosciences’s price movement after its last earnings report?
Cogent Biosciences reported an EPS of -$0.5 in its last earnings report, beating expectations of -$0.516. Following the earnings report the stock price went down -4.908%.
Which hedge fund is a major shareholder of Cogent Biosciences?
Currently, no hedge funds are holding shares in COGT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cogent Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$48.70 (36.91% Upside)
$48.70 (36.91% Upside)
Blogger Sentiment
Bullish
COGT Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 9.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $12.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.9%
Last 30 Days ▲ 13.5%
Last 30 Days ▲ 13.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
339.63%
12-Months-Change
Fundamentals
Return on Equity
-95.40%
Trailing 12-Months
Asset Growth
10.92%
Trailing 12-Months
Company Description
Cogent Biosciences
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
COGT Stock 12 Month Forecast
Average Price Target
$48.70
▲(36.91% Upside)
Technical Analysis
IDEAYA Biosciences
―
Beam Therapeutics
―
Disc Medicine
―
Harmony Biosciences Holdings
―
Immunocore Holdings
―
Ownership Overview
Currently, No data available
---